Progress towards recombinant anti-infective antibodies.

Area of Science:

• Biotechnology
• Immunology
• Pharmacology

Background:

• The global monoclonal antibody (mAb) therapeutics market was valued at $11.2 billion in 2004, demonstrating significant growth.
• Streamlined development and regulatory processes facilitate mAb production.
• Despite market growth, few approved mAbs target infectious diseases, indicating a significant unmet need.

Purpose of the Study:

• To highlight the growing market and therapeutic potential of monoclonal antibodies.
• To explore the increasing interest and development of mAbs for infectious disease treatment.
• To discuss advancements in antibody technology and their implications for future anti-infective therapeutics.

Main Methods:

• Market analysis of monoclonal antibody therapeutics.
• Review of current FDA-approved antibodies and clinical trial products.
• Analysis of patents and patent applications related to anti-infective antibody technology.

Main Results:

• The mAb market showed a 42% growth rate from 2000-2004, projected to reach $34 billion by 2010.
• Respiratory Syncytial Virus (RSV) antibody Synagis achieved $1.1 billion in sales, demonstrating market viability.
• There is a notable increase in academic, governmental, and commercial interest in developing mAbs for infectious diseases.

Conclusions:

• The success of anti-RSV passive immunization encourages further development of mAb-based anti-infectives.
• Advances in antibody technology, including mAb cocktails and broadly specific mAbs, are key to future anti-infective strategies.
• Patent activity suggests a strong pipeline for novel monoclonal antibody anti-infective therapeutics.